Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

NCT07052266 · View on ClinicalTrials.gov ↗

Study Summary

The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evaluate the acceptability of BRCA1/2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.

Interventions

  • GENETIC MyRisk Hereditary Cancer Test

Study Locations (5)

New York

  • Reproductive Medicine — Brooklyn
  • NewYork-Presbyterian Weill Cornell Medicine — Brooklyn
  • Reproductive Medicine — New York
  • Weill Cornell Medicine — New York
  • NewYork-Presbyterian Weill Cornell Medicine Queens — Queens

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2025-09-02
Est. Completion 2028-12
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07052266

The ClinicalTrials.gov registry entry for NCT07052266 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 679 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Hereditary Cancer Syndromes appearing as the primary indexed condition, and to 1 intervention — of which MyRisk Hereditary Cancer Test is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07052266 reports 5 study locations spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07052266 about?

NCT07052266 is a clinical study titled "Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening". The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evalu...

What is the current status of trial NCT07052266?

This trial is currently recruiting. It is a NA study. The enrollment target is 550 participants. The study started on 2025-09-02. Estimated completion is 2028-12.

What conditions does trial NCT07052266 study?

This clinical trial studies the following conditions: Hereditary Cancer Syndromes. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07052266?

The interventions under investigation include: MyRisk Hereditary Cancer Test (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07052266?

This trial is sponsored by Weill Medical College of Cornell University, which has 679 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07052266 being conducted?

This trial has 5 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial